Search

Your search keyword '"Stieler J"' showing total 158 results
Start Over Author "Stieler J"
158 results on '"Stieler J"'

2. Myelin insulation as a risk factor for axonal degeneration in autoimmune demyelinating disease

Author

Schäffner, E., Bosch-Queralt, M., Edgar, J., Lehning, M., Strauß, J., Fleischer, N., Kungl, T., Wieghofer, P., Berghoff, S., Reinert, T., Krueger, M., Morawski, M., Möbius, W., Barrantes-Freer, A., Stieler, J., Sun, T., Saher, G., Schwab, M., Wrede, C., Frosch, M., Prinz, M., Reich, D., Flügel, A., Stadelmann, C., Fledrich, R., Nave, K., and Stassart, R.

Subjects
Mice, metabolism [Myelin Sheath], Risk Factors, Animals, Humans, pathology [Encephalomyelitis, Autoimmune, Experimental], ddc:610, pathology [Multiple Sclerosis], metabolism [Axons]
Abstract

Axonal degeneration determines the clinical outcome of multiple sclerosis and is thought to result from exposure of denuded axons to immune-mediated damage. Therefore, myelin is widely considered to be a protective structure for axons in multiple sclerosis. Myelinated axons also depend on oligodendrocytes, which provide metabolic and structural support to the axonal compartment. Given that axonal pathology in multiple sclerosis is already visible at early disease stages, before overt demyelination, we reasoned that autoimmune inflammation may disrupt oligodendroglial support mechanisms and hence primarily affect axons insulated by myelin. Here, we studied axonal pathology as a function of myelination in human multiple sclerosis and mouse models of autoimmune encephalomyelitis with genetically altered myelination. We demonstrate that myelin ensheathment itself becomes detrimental for axonal survival and increases the risk of axons degenerating in an autoimmune environment. This challenges the view of myelin as a solely protective structure and suggests that axonal dependence on oligodendroglial support can become fatal when myelin is under inflammatory attack.

Published
2023
Full Text
View/download PDF

28. Conko-006: a Randomized Double-Blinded Phase Iib-Study of Adjuvant Therapy with Gemcitabine + Sorafenib/Placebo for Patients with R1-Resection of Pancreatic Cancer

Author

Sinn, M., primary, Liersch, T., additional, Gellert, K., additional, Riess, H., additional, Stübs, P., additional, Waldschmidt, D.T., additional, Pelzer, U., additional, Stieler, J., additional, Striefler, J.K., additional, Bahra, M., additional, Dörken, B., additional, and Oettle, H., additional

Published
2014
Full Text
View/download PDF

35. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial

Author

Riess, H., primary, Pelzer, U., additional, Deutschinoff, G., additional, Opitz, B., additional, Stauch, M., additional, Reitzig, P., additional, Hahnfeld, S., additional, Hilbig, A., additional, Stieler, J., additional, and Oettle, H., additional

Published
2009
Full Text
View/download PDF

48. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003)

Author

Oettle, H., primary, Pelzer, U., additional, Stieler, J., additional, Hilbig, A., additional, Roll, L., additional, Schwaner, I., additional, Adler, M., additional, Detken, S., additional, Dörken, B., additional, and Riess, H., additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results